Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Subsequent anti-HCC treatment among patients having received lenvatinib or sorafenib as first systemic treatment
| Lenvatinib (15/44, 34.1%) | Sorafenib (46/88, 52.3%) |
p-value 0.048 |
|
|---|---|---|---|
| Systemic treatment | 12 (80.0%) | 43 (93.5%) | |
| Sorafenib | 9 (75.0%) | 0 (0.0%) | |
| Regorafenib | 0 (0.0%) | 34 (79.1%) | |
| Nivolumab | 0 (0.0%) | 6 (14.0%) | |
| Dendritic cell immunotherapy | 1 (8.3%) | 0 (0.0%) | |
| Others | 2 (16.7%) | 3 (7.0%) | |
| Locoregional treatment only | 3 (20.0%) | 3 (6.5%) |
Data are presented as number (%)
